PharmAthene, Inc.

ANNAPOLIS, Md., May 8, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the first quarter of 2013. "We made steady progress in our biodefense programs this quarter," said Eric I. Richman, President ... read more

ANNAPOLIS, Md., May 6, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that its financial and operating results for the first quarter of 2013 will be released on Wednesday, May 8, 2013. PharmAthene management ... read more

ANNAPOLIS, Md., April 17, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the Company's recombinant butyrylcholinesterase (rBChE) bioscavenger demonstrating that ... read more

ANNAPOLIS, Md., March 13, 2013 /PRNewswire/ -- Year-End 2012 Highlights -- Received favorable final order and judgment from Delaware Chancery Court against SIGA Technologies -- Accelerated funding for bioscavenger program under Department of Defense ... read more

ANNAPOLIS, Md., March 12, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2012 will be released on Wednesday, March 13, 2013. PharmAthene management will host ... read more

ANNAPOLIS, Md., Jan. 17, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the Noble Financial Capital Markets Ninth Annual Equity Conference on ... read more

ANNAPOLIS, Md., Jan. 14, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it has entered into an exclusive commercial license for the use of Percivia's proprietary PER.C6(®) technology platform in the production of PharmAthene's next generation ... read more

ANNAPOLIS, Md., Jan. 10, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced that the Delaware Supreme Court heard oral arguments today related to both parties' appeal in the Company's on-going litigation against SIGA Technologies. SIGA appealed the final judgment in favor of PharmAthene issued by the Delaware Court ... read more